4 Undervalued Biotechnology & Medical Research Stocks for Friday, August 09
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Friday, August 09 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Commentary & Analysis
5 Undervalued Biotechnology & Medical Research Stocks for Friday, June 28
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Friday, June 28 based on AAII’s Stock Grades.Jack Gilleland
7 Undervalued Biotechnology & Medical Research Stocks for Thursday, May 23
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Thursday, May 23 based on AAII’s Stock Grades.Jenna Brashear
6 Undervalued Biotechnology & Medical Research Stocks for Tuesday, April 16
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Tuesday, April 16 based on AAII’s Stock Grades.Eunice Kim
7 Undervalued Biotechnology & Medical Research Stocks for Monday, March 04
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Monday, March 04 based on AAII’s Stock Grades.Grace Malone
Financial Summary
| Share Statistics | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.4 | $252.6 | 9% |
|
| Shares Out (Mil) | 24.3 | 52.3 | 34% |
|
| Institutional Ownership | 93.1% | 92.1% | 63% |
|
| Float (Mil) | 16.6 | 40.2 | 26% |
|
| Beta | 0.22 | 0.95 | 13% |
|
| Avg Daily Volume (000s) | 418 | 455 | 56% |
|
| Price Change (52-week) |
(37.1%) | 52.9% | 21% |
|
| Growth | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 45.6% | (15.6%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.160) | ($0.760) | ($1.010) | |
| Month Ago EPS | ($0.160) | ($0.760) | ($1.010) | |
| # Rev Up | na | 1 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | ($0.450) | ($1.860) | ($2.100) | |
| Year/Year Chg | 35.6% | (73.8%) | (55.2%) | |
| Financials | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($20) | ($43) | 24% |
|
| EPS (TTM) | ($1.571) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($31) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($27) | $180 | 1% |
|
| Valuation | KTTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.21 | 2.56 | 3% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (55.6%) | (49.8%) | 11% |
|
| ROE | (58.2%) | (55.5%) | 14% |
|
| Liabilities to Assets | 2.7% | 30.3% | 1% |
|
| F-Score | 3 | 3 | 19% |
|
Pasithea Therapeutics Corp. did not pass any screens on 7/31/2026.
